- Paper Report
- Open Access
GI toxicity of rofecoxib compared to naproxen
- Richard Brasington1
© Biomed Central Ltd 2001
- Published: 8 January 2001
- GI toxicity
The hypothesis that selective inhibitors of cyclo-oxegenase (COX)-2 (coxibs) would have less serious upper gastrointestinal (GI) toxicity than traditional non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) has recently been affirmed for celecoxib (see Additional information). This study tests the hypothesis for rofecoxib in rheumatoid arthritis (RA).
Confirmed GI events were less with rofecoxib than naproxen (2.1 versus 4.5 per 100 patient-years, relative risk 0.5), as were the rates of complicated events (0.6 versus 1.4 per 100 patient-years, relative risk 0.4). The incidence of myocardial infarction (MI) was higher with rofecoxib than naproxen (0.4% versus 0.1%, relative risk 0.2).
Prospective, randomized controlled trial with active comparator
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255 (PaperReport).
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien RK, Weaver A, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2001, 343: 1521-1528.Google Scholar